Incannex Healthcare Updates Business Address in 8-K Filing
Ticker: IXHL · Form: 8-K · Filed: Jan 18, 2024 · CIK: 1873875
| Field | Detail |
|---|---|
| Company | Incannex Healthcare Inc. (IXHL) |
| Form Type | 8-K |
| Filed Date | Jan 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, address-change
TL;DR
**Incannex Healthcare just filed an 8-K to update their business address, no big deal.**
AI Summary
Incannex Healthcare Inc. filed an 8-K on January 18, 2024, to update its business address to Suite 105, 8 Century Circuit, Norwest, NSW 2153, Australia. This administrative change, while minor, ensures that all official communications and regulatory filings reflect the company's current operational location. For investors, this simply means the company is maintaining accurate public records, which is a basic expectation for a Nasdaq-listed entity like IXHL.
Why It Matters
This filing is an administrative update, ensuring Incannex Healthcare's public records, including its business address, are current and accurate. It reflects good corporate governance but has no direct impact on the company's financial performance or operations.
Risk Assessment
Risk Level: low — This filing is purely administrative, updating the company's business address, and carries no inherent financial or operational risk.
Analyst Insight
A smart investor would note this as a routine administrative update, confirming the company's adherence to regulatory requirements, but it provides no new information to alter investment decisions regarding Incannex Healthcare Inc. (IXHL).
Key Numbers
- $0.0001 — par value per share (par value of Incannex Healthcare Inc.'s common stock)
Key Players & Entities
- Incannex Healthcare Inc. (company) — the registrant filing the 8-K
- January 18, 2024 (date) — date of report
- Suite 105, 8 Century Circuit, Norwest, NSW 2153 Australia (address) — new principal executive offices address
- Nasdaq Stock Market LLC (company) — exchange where Incannex Healthcare's common stock is registered
- $0.0001 (dollar_amount) — par value per share of common stock
FAQ
What is the primary purpose of Incannex Healthcare Inc.'s 8-K filing dated January 18, 2024?
The primary purpose of Incannex Healthcare Inc.'s 8-K filing dated January 18, 2024, is to report an update to its principal executive offices address, as stated under 'Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' and 'Item 8.01. Other Events'.
What is the new business address for Incannex Healthcare Inc. as reported in this 8-K?
The new business address for Incannex Healthcare Inc. is Suite 105, 8 Century Circuit, Norwest, NSW 2153 Australia, as specified in the filing.
On which stock exchange is Incannex Healthcare Inc.'s Common Stock registered?
Incannex Healthcare Inc.'s Common Stock, with a $0.0001 par value per share, is registered on The Nasdaq Stock Market LLC, as indicated in the 'Securities registered pursuant to Section 12(b) of the Act' section.
What is the trading symbol for Incannex Healthcare Inc. on The Nasdaq Stock Market LLC?
The trading symbol for Incannex Healthcare Inc. on The Nasdaq Stock Market LLC is IXHL, as listed under 'Title of each class' and 'Trading Symbol' in the filing.
Does this 8-K filing indicate any changes in the company's financial statements or executive officers?
No, this 8-K filing does not indicate any changes in the company's financial statements or executive officers. The filing primarily addresses an update to the business address and is categorized under 'Other Events' and 'Financial Statements and Exhibits' for administrative purposes, without detailing any financial or personnel changes.
Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 11.4 · Accepted 2024-01-18 09:08:33
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IXHL The Nasdaq
Filing Documents
- ea191799-8k_incannex.htm (8-K) — 26KB
- ea191799ex99-1_incannex.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-24-004298.txt ( ) — 226KB
- ixhl-20240118.xsd (EX-101.SCH) — 3KB
- ixhl-20240118_lab.xml (EX-101.LAB) — 33KB
- ixhl-20240118_pre.xml (EX-101.PRE) — 22KB
- ea191799-8k_incannex_htm.xml (XML) — 3KB
01
Item 8.01 On January 18, 2024, Incannex Healthcare Inc. announced that it had completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial. Further information is included in the press release attached as Exhibit 99.1 hereto, which is incorporated by reference into this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of Incannex Healthcare Inc., dated January 18, 2024 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Incannex Healthcare Inc. Date: January 18, 2024 /s/ Joel Latham Name: Joel Latham Title: Chief Executive Officer and President 2